Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience

Retrospective review data from 183 patients with psoriasis and/or hidradenitis suppurativa from a UK tertiary dermatology centre, suggests biologic therapy does not confer a significant increased risk of contracting severe Covid‐19 in this cohort. This is in line with a growing body of evidence whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, S., Karponis, D., Wali, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236977/
https://www.ncbi.nlm.nih.gov/pubmed/34235510
http://dx.doi.org/10.1002/ski2.54
_version_ 1783714650853998592
author Khan, S.
Karponis, D.
Wali, G.
author_facet Khan, S.
Karponis, D.
Wali, G.
author_sort Khan, S.
collection PubMed
description Retrospective review data from 183 patients with psoriasis and/or hidradenitis suppurativa from a UK tertiary dermatology centre, suggests biologic therapy does not confer a significant increased risk of contracting severe Covid‐19 in this cohort. This is in line with a growing body of evidence which indicates that it is safe to continue using biologic therapies during the pandemic.[Image: see text]
format Online
Article
Text
id pubmed-8236977
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82369772021-06-28 Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience Khan, S. Karponis, D. Wali, G. Skin Health Dis Letters to the Editor Retrospective review data from 183 patients with psoriasis and/or hidradenitis suppurativa from a UK tertiary dermatology centre, suggests biologic therapy does not confer a significant increased risk of contracting severe Covid‐19 in this cohort. This is in line with a growing body of evidence which indicates that it is safe to continue using biologic therapies during the pandemic.[Image: see text] John Wiley and Sons Inc. 2021-06-09 /pmc/articles/PMC8236977/ /pubmed/34235510 http://dx.doi.org/10.1002/ski2.54 Text en © 2021 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letters to the Editor
Khan, S.
Karponis, D.
Wali, G.
Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience
title Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience
title_full Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience
title_fullStr Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience
title_full_unstemmed Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience
title_short Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: A UK dermatology tertiary centre experience
title_sort outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the covid‐19 pandemic: a uk dermatology tertiary centre experience
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236977/
https://www.ncbi.nlm.nih.gov/pubmed/34235510
http://dx.doi.org/10.1002/ski2.54
work_keys_str_mv AT khans outcomesofpatientswithchronicplaquepsoriasisandhidradenitissuppurativaonbiologictherapyduringthecovid19pandemicaukdermatologytertiarycentreexperience
AT karponisd outcomesofpatientswithchronicplaquepsoriasisandhidradenitissuppurativaonbiologictherapyduringthecovid19pandemicaukdermatologytertiarycentreexperience
AT walig outcomesofpatientswithchronicplaquepsoriasisandhidradenitissuppurativaonbiologictherapyduringthecovid19pandemicaukdermatologytertiarycentreexperience

Ejemplares similares